Results 231 to 240 of about 118,861 (266)

HIV Protease Inhibitors: Present and Future

Future Virology, 2011
Antiretroviral therapy offers many options, largely based on the next-generation protease inhibitors (PIs). Early PI-based treatments involve high pill burdens and dosing schedules, and concerns of long-term toxicities are well established. In patients who have already achieved viral suppression, novel agents and strategies should be used to simplify ...
Pizzocolo Cecilia, Castagna A, Lazzarin Adriano   +2 more
openaire   +1 more source

The synthesis of novel HIV-protease inhibitors

Bioorganic & Medicinal Chemistry, 1994
The syntheses, enzyme inhibition and antiviral activity of potent HIV-protease inhibitors containing novel beta-hydroxy ether and thioethers based on the transition state mimetic concept are discussed.
V M, Girijavallabhan, F, Bennett, N M, Patel, A K, Ganguly, B, Dasmahapatra, N, Butkiewicz, A, Hart   +6 more
openaire   +2 more sources

Oral Delivery of HIV-Protease Inhibitors

Critical Reviews™ in Therapeutic Drug Carrier Systems, 2000
Strategies for optimizing the oral delivery of HIV-protease inhibitors draw from drug discovery efforts in molecular design, drug development tools in dosage formulation, and dosage regimen considerations in clinical medicine. This review outlines the evolution of these strategies for drugs that have been approved for human use, drug candidates still ...
L Y, Li, B H, Stewart, D, Fleisher
openaire   +2 more sources

Dyslipidemia in the era of HIV protease inhibitors

Progress in Cardiovascular Diseases, 2003
Human immunodeficiency virus protease inhibitors are associated with metabolic abnormalities that may increase risk of atherosclerotic vascular disease, including dyslipidemia, insulin resistance, and central obesity. Dyslipidemia, characterized by hypercholesterolemia and hypertriglyceridemia, small low- and high-density lipoprotein particles, and in ...
openaire   +2 more sources

Ongoing trials in HIV protease inhibitors

Expert Opinion on Investigational Drugs, 2000
The development of antiretrovirals has led to a revolution in the care of patients infected with HIV. What was once a uniformly fatal syndrome has become a more treatable, chronic, infectious disease. Central to this revolution have been the protease inhibitors, a class of drugs with potent antiretroviral activity.
openaire   +2 more sources

HIV protease inhibitors

Current Opinion in Infectious Diseases, 1997
Akhteruzzaman Molla, Anthony Japour
openaire   +3 more sources

HIV-1 protease inhibitors

Drug Discovery Today, 2001
openaire   +2 more sources

HIV-protease-inhibitors

Reactions Weekly, 2021
openaire   +1 more source

Protease inhibitors and cardiovascular outcomes in patients with HIV-1

Lancet, The, 2002
Anne C Moorman
exaly  

Inhibition of HIV‐2 Protease by HIV‐1 Protease Inhibitors in Clinical Use

Chemical Biology and Drug Design, 2008
Ernesto Freire
exaly